Surgery
Volume 122, Issue 6 , Pages 1075-1082 , December 1997

Survival and daily physical activity in patients treated for advanced midgut carcinoid tumors

References 

  1. Moertel CG. An Odyssey in the land of small tumors. J Clin Oncol. 1987;5:1503–1522
  2. Makridis C, Öberg K, Juhlin C, Rastad J, Johansson H, Lörelius LE, et al.  Surgical treatment of mid-gut carcinoid tumors. World J Surg. 1990;14:377–385
  3. Anthony PP, Drury RAB. Elastic vascular sclerosis of mesenteric blood vessels in argentaffin carcinoma. J Clin Pathol. 1970;23:110–118
  4. Eckhauser FE, Argenta LC, Strodel WE, Wheeler RH, Bull FE, Appelman HD, et al.  Mesenteric angiopathy, intestinal gangrene, and midgut carcinoids. Surgery. 1981;90:720–728
  5. Graham-Smith DF. The carcinoid syndrome. Am J Cardiol. 1968;21:376–387
  6. Norheim I, Öberg K, Theodorsson-Norheim E, Lindgren PG, Lundin L, Lundqvist G, et al.  Malignant carcinoid tumors: an analysis of 103 patients with regard to tumor localization, hormone production, and survival. Ann Surg. 1987;206:115–125
  7. Pellikka PA, Tajik AJ, Khandheria BK, Seward JB, Callahan JA, Pilot HC, et al.  Carcinoid heart disease: clinical and echocardiographic spectrum in 74 patients. Circulation. 1993;87:1188–1196
  8. Martin JK, Moertel CG, Adson MA, Schutt AJ. Surgical treatment of functioning metastatic carcinoid tumors. Arch Surg. 1983;118:537–543
  9. McEntee GP, Nagorney DM, Kvols LK, Moertel CG, Grant CS. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery. 1990;108:1091–1096
  10. Ahlman H, Wängberg B, Jansson S, Stenqvist O, Geterud K, Tylen U, et al.  Management of disseminated midgut carcinoid tumours. Digestion. 1991;49:78–96
  11. Grønbech JE, Bergan A. Review: the role of resective surgery in the treatment of the carcinoid syndrome. Scand J Gastroenterol. 1992;27:433–437
  12. Sloan DA, Schwartz RW, Kenady DE. Surgical therapy for endocrine tumors of abdominal origin. Curr Opin Oncol. 1993;5:100–109
  13. Öberg K, Funa K, Alm G. Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with midgut carcinoid tumors and the carcinoid syndrome. N Engl J Med. 1983;309:129–133
  14. Kvols LK, Moertel CG, O'Connell MJ, Schutt AJ, Rubin J, Hahn RG. Treatment of the malignant carcinoid syndrome: evaluation of a long acting somatostatin analogue. N Engl J Med. 1986;315:663–666
  15. Kvols LK. Therapy of the malignant carcinoid syndrome. Endocrinol Metabol Clin North Am. 1989;18:557–568
  16. Öberg K, Eriksson B. The role of interferons in the management of carcinoid tumors. Acta Oncol. 1991;30:519–522
  17. Tiensuu Janson E, Ahlström H, Andersson T, Öberg K. Octreotide and interferon alpha: a new combination for the treatment of malignant carcinoid tumors. Eur J Cancer. 1992;10:1647–1650
  18. Moertel CG, Sauer WG, Dockerty MB, Baggenstoss AH. Life history of the carcinoid tumor of the small intestine. Cancer. 1961;14:901–912
  19. Davis Z, Moertel CG, McIlrath DC. The malignant carcinoid syndrome. Surg Gynecol Obstet. 1973;137:637–644
  20. McDermott E, Guduric B, Brennan M. Prognostic variables in patients with gastrointestinal carcinoid tumors. Br J Surg. 1994;81:1007–1009
  21. Lunderquist A, Ericsson M, Nobin Sanden G. Gelfoam powder embolization of the hepatic artery in liver metastases of carcinoid tumors. Radiologie. 1982;22:65–70
  22. Makridis C, Rastad J, Öberg K, Åkerström G. Progression of metastases and symptom improvement from laparotomy in midgut carcinoid tumors. World J Surg. 1996;20:900–907
  23. Lundin L, Hansson H-E, Landelius J, Öberg K. Surgical treatment of carcinoid heart disease. J Thorac Cardiovasc Surg. 1990;100:552–561

☆ Supported by the Swedish Cancer Society.

☆☆ Presented at the Eighteenth Annual Meeting of the American Association of Endocrine Surgeons, Baltimore, Md., April 6–8, 1997.

PII: S0039-6060(97)90211-7

Surgery
Volume 122, Issue 6 , Pages 1075-1082 , December 1997

Article Tools